Michel Seymour

21.0k total citations · 6 hit papers
239 papers, 12.5k citations indexed

About

Michel Seymour is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Michel Seymour has authored 239 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 51 papers in Surgery. Recurrent topics in Michel Seymour's work include Colorectal Cancer Treatments and Studies (126 papers), Gastric Cancer Management and Outcomes (52 papers) and Cancer Treatment and Pharmacology (37 papers). Michel Seymour is often cited by papers focused on Colorectal Cancer Treatments and Studies (126 papers), Gastric Cancer Management and Outcomes (52 papers) and Cancer Treatment and Pharmacology (37 papers). Michel Seymour collaborates with scholars based in United Kingdom, United States and Canada. Michel Seymour's co-authors include Philip Quirke, Susan D. Richman, Aimery de Gramont, Jim Cassidy, Filippo de Braud, D. Papamichael, Tim Maughan, Christophe Louvet, Abdel Hmissi and H. Cortés-Funes and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michel Seymour

221 papers receiving 12.1k citations

Hit Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin a... 2000 2026 2008 2017 2000 2014 2014 2011 2016 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
    2000 3.0k citations Michel Seymour et al. Journal of Clinical Oncology profile →
  2. The prevalence and outcomes of frailty in older cancer patients: a systematic review
    2014 683 citations Michel Seymour et al. Annals of Oncology profile →
  3. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
    2014 534 citations Sabine Venderbosch, Irıs D. Nagtegaal et al. Clinical Cancer Research profile →
  4. Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
    2011 505 citations Gordon Hutchins, Katie Southward et al. Journal of Clinical Oncology profile →
  5. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
    2016 434 citations Tim Maughan, Richard Adams et al. profile →
  6. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
    2023 181 citations Dion Morton, Michel Seymour et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Seymour United Kingdom 44 9.1k 3.6k 3.1k 2.8k 1.9k 239 12.5k
Christophe Tournigand France 42 7.0k 0.8× 3.0k 0.8× 2.4k 0.8× 1.2k 0.4× 2.0k 1.0× 256 9.5k
V.E.P.P. Lemmens Netherlands 64 7.4k 0.8× 3.9k 1.1× 5.7k 1.8× 1.8k 0.7× 647 0.3× 308 13.9k
Roberto Labianca Italy 65 15.4k 1.7× 5.8k 1.6× 4.5k 1.5× 5.2k 1.9× 1.5k 0.7× 323 21.9k
Jean Faivre France 59 7.6k 0.8× 3.8k 1.1× 3.9k 1.3× 3.1k 1.1× 1.3k 0.7× 353 13.3k
Franck Bonnetain France 51 6.5k 0.7× 4.2k 1.2× 4.6k 1.5× 822 0.3× 770 0.4× 288 11.2k
Marwan Fakih United States 52 6.3k 0.7× 2.4k 0.7× 1.5k 0.5× 2.5k 0.9× 614 0.3× 426 9.8k
Miriam Koopman Netherlands 41 5.7k 0.6× 1.9k 0.5× 1.8k 0.6× 2.0k 0.7× 1.4k 0.7× 222 8.0k
Axel Grothey United States 57 14.2k 1.6× 4.9k 1.4× 3.5k 1.1× 3.9k 1.4× 3.3k 1.7× 331 18.6k
Aimery de Gramont France 64 20.1k 2.2× 6.8k 1.9× 5.3k 1.7× 4.4k 1.6× 4.7k 2.4× 333 25.0k
Daniel G. Haller United States 68 16.8k 1.8× 9.2k 2.5× 8.7k 2.8× 4.6k 1.7× 1.6k 0.8× 243 25.2k

Countries citing papers authored by Michel Seymour

Since Specialization
Citations

This map shows the geographic impact of Michel Seymour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Seymour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Seymour more than expected).

Fields of papers citing papers by Michel Seymour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Seymour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Seymour. The network helps show where Michel Seymour may publish in the future.

Co-authorship network of co-authors of Michel Seymour

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Seymour. A scholar is included among the top collaborators of Michel Seymour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Seymour. Michel Seymour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elliott, Faye, Philip Quirke, Michel Seymour, et al.. (2024). 552P Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial. Annals of Oncology. 35. S456–S457. 1 indexed citations
2.
Baxter, Mark, Lindsay C. Spender, Shaun Walsh, et al.. (2023). Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial. Cancers. 15(9). 2591–2591. 2 indexed citations
3.
Morton, Dion, Michel Seymour, Laura Magill, et al.. (2023). Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. Journal of Clinical Oncology. 41(8). 1541–1552. 181 indexed citations breakdown →
4.
Swinson, Daniel, David A. Cairns, Mark Baxter, et al.. (2021). Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. Journal of Geriatric Oncology. 13(3). 287–293. 12 indexed citations
5.
Adams, Richard, Ewan Brown, Louise Brown, et al.. (2017). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. ˜The œLancet. Gastroenterology & hepatology. 3(3). 162–171. 37 indexed citations
6.
Law, Kate, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. ed20–ed20. 6 indexed citations
7.
Richman, Susan D., Katie Southward, Philip Chambers, et al.. (2015). HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. The Journal of Pathology. 238(4). 562–570. 183 indexed citations
8.
Smith, Christopher G., David J. Fisher, Rebecca Harris, et al.. (2015). Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research. 21(15). 3453–3461. 16 indexed citations
9.
Venderbosch, Sabine, Irıs D. Nagtegaal, Tim Maughan, et al.. (2014). Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research. 20(20). 5322–5330. 534 indexed citations breakdown →
10.
Hutchins, Gordon, Katie Southward, Kelly Handley, et al.. (2011). Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology. 29(10). 1261–1270. 505 indexed citations breakdown →
11.
Allan, James M., Julian Adlard, Jonathan Bury, et al.. (2008). MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. International Journal of Cancer. 123(10). 2456–2459. 41 indexed citations
12.
Seymour, Michel. (2008). Pour une constitution québécoise / Rapport de la Commission de consultation sur les pratiques d’accommodement reliées aux différences culturelles de Charles Taylor et Gérard Bouchard. 16–17. 2 indexed citations
13.
Andrew, Caroline, Linda Cardinal, Nicholas Brown, et al.. (2007). Managing Diversity : Practices of Citizenship. BiblioBoard Library Catalog (Open Research Library). 6 indexed citations
14.
James, R.D., David Kerr, JA Ledermann, et al.. (2000). Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. UCL Discovery (University College London). 17 indexed citations
15.
Leonard, Pauline, et al.. (2000). Phase II study of irinotecan and high dose infusional 5- fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer. UCL Discovery (University College London).
16.
Ledermann, JA, T.S. Maughan, Daniel Kerr, et al.. (1999). Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. UCL Discovery (University College London). 41 indexed citations
17.
18.
Seymour, Michel, et al.. (1994). Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. British Journal of Cancer. 69(1). 191–195. 57 indexed citations
19.
Thompson, Paul, Michel Seymour, N. Deasy, et al.. (1991). A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. British Journal of Cancer. 64(3). 603–605. 33 indexed citations
20.
Seymour, Michel, et al.. (1985). Controlled trial of Iodosorb in chronic venous ulcers.. BMJ. 291(6491). 308–310. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Tournigand Breakdown of academic impact, for papers by V.E.P.P. Lemmens Breakdown of academic impact, for papers by Roberto Labianca Breakdown of academic impact, for papers by Jean Faivre Breakdown of academic impact, for papers by Franck Bonnetain Breakdown of academic impact, for papers by Marwan Fakih Breakdown of academic impact, for papers by Miriam Koopman Breakdown of academic impact, for papers by Axel Grothey Breakdown of academic impact, for papers by Aimery de Gramont Breakdown of academic impact, for papers by Daniel G. Haller
Rankless by CCL
2026